{"filing":{"accession_number":"0001731122-26-001144","cik":"0001553788","ticker":"SBEVW","company_name":"Endovia Health Sciences, Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-24","primary_document":"e7891_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226001144/e7891_8k.htm"},"events":[{"id":29350,"run_id":26868,"accession_number":"0001731122-26-001144","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces achievement of the first FDA regulatory milestone for CannEpil®—establishment of an Investigational New Animal Drug (INAD) file—under a collaboration agreement with Lupvindol Biosciences. This represents a material operational and strategic development milestone for the Company's veterinary pharmaceutical program, formally initiating FDA regulatory engagement. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the Company's ability to execute its development strategy and advance its new health sciences platform.","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31602,"accession_number":"0001731122-26-001144","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces achievement of the first FDA regulatory milestone for CannEpil®—establishment of an Investigational New Animal Drug (INAD) file—under a collaboration agreement with Lupvindol Biosciences. This represents a material operational and strategic development milestone for the Company's veterinary pharmaceutical program, formally initiating FDA regulatory engagement. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the Company's ability to execute its development strategy and advance its new health sciences platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T12:32:57.054527+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31602,"accession_number":"0001731122-26-001144","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces achievement of the first FDA regulatory milestone for CannEpil®—establishment of an Investigational New Animal Drug (INAD) file—under a collaboration agreement with Lupvindol Biosciences. This represents a material operational and strategic development milestone for the Company's veterinary pharmaceutical program, formally initiating FDA regulatory engagement. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the Company's ability to execute its development strategy and advance its new health sciences platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T12:32:57.054527+00:00","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-08-25"}]}